Home Alzheimer’s Disease Positive Results from Phase III PROfound Trial of Olaparib Demonstrate Improvements in...

Positive Results from Phase III PROfound Trial of Olaparib Demonstrate Improvements in OS

Positive results from the phase III PROfound trial of olaparib (Lynparza) in men with metastatic castration-resistant prostate cancer (mCRPC) who have a homologous repair gene mutation (HRRm) and have progressed on prior treatment with new hormonal agent treatments such as enzalutamide (Xtandi) and abiraterone (Zytiga) were announced by AstraZeneca and MSD, the developers of the agent.1

Results from the trial demonstrated a statistically significant and clinically meaningful improvement in the secondary endpoint of overall survival (OS) with olaparib versus enzalutamide or abiraterone in men with mCRPC selected for BRCA1/2 or ATM gene mutations.

“Overall survival in metastatic castration-resistant prostate cancer has remained extremely challenging to achieve,” José Baselga, executive vice president for Oncology R&D, said in a press release. “We are thrilled by these…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments